One Weak Spot, One Upgrade: Wells Fargo on Zimmer Biomet (ZBH)

Wells Fargo upgraded Zimmer Biomet (ZBH) to Overweight with a $123 price target, citing growth in hips and other products. ZBH's knee sales fell 3.1% in Q3 2026, but the company raised its 2026 EPS guidance to $8.50-$8.60. The Fed may raise rates in December, with officials divided on the size of the hike.

Original reporting
Published Nov 19, 2026, 2:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 19, 2026, 2:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
One Weak Spot, One Upgrade: Wells Fargo on Zimmer Biomet (ZBH) — source image
Decision brief

The 30-second read

$ZBHBullishMed
01

Why it matters

For ZBH, the actionable element is the Wells Fargo rating upgrade and raised price target, anchored to a specific product catalyst (Monogram robot) intended to address the company’s weakest segment (knees).

02

Market read

Traders can use the upgrade and target change to reassess near-term sentiment and the probability-weighting of the knee recovery catalyst.

03

What to watch

The article notes knee sales fell 3.1% in Q3 2026 while hips grew 6.0%, so investors may still need evidence that knees are stabilizing before the 2027 robot launch.

Relevance 7/10Novelty 5/10Timing: after-hours/next-session positioning following the Nov. 17 upgrade and target change

Background

The piece frames Zimmer Biomet’s analyst upgrade within a broader market narrative about Fed rate expectations and higher Treasury yields.

Company-level read

Ticker impact

$ZBHBullishMedium confidence
Context

Wells Fargo upgraded Zimmer Biomet to Overweight on Nov. 17, lifting its price target to $123 and citing the Monogram knee robot as the fix.

Expected impact

Likely near-term support as traders price in improved knee recovery expectations tied to the Monogram launch timeline.

Evidence & confidence

The article provides a specific analyst action (rating change and price target) plus a concrete operational thesis (knee weakness, Monogram launch) that can influence positioning ahead of future updates.

Market effects

Orthopedic medtech sentiment may improve modestly if investors view robotics as a credible catalyst for knee demand stabilization.

No direct regional transmission beyond general US rate and equity risk sentiment discussed in the piece.

Limited, as the core catalyst is company-specific (Monogram launch) and the macro context is US-focused.

Counterpoint

The upgrade may be premature if knee weakness persists longer than the Monogram timeline, making the catalyst more speculative than the rating implies.

Key entities

  • Zimmer Biomet

    Orthopedic implant and sports medicine company; subject of the Wells Fargo upgrade and product-catalyst thesis.

  • Wells Fargo

    Upgraded ZBH to Overweight and raised its price target to $123, citing Monogram robot for knee recovery.

  • Monogram robot

    Robotic system expected to launch in the first half of 2027, positioned as the fix for knee weakness.

Related articles

$ZBHMed

Zimmer submits Monogram robot to FDA

Zimmer Biomet submitted its autonomous Monogram robot for FDA clearance, aiming for approval in 2027. The company acquired Monogram in 2025 for $177M. Clinical trials showed no safety events, with potential time savings and accuracy improvements. CEO Ivan Tornos expects FDA review may involve back-and-forth due to the technology's novelty.

$ZBHMed

Why is Zimmer Biomet stock climbing today?

Zimmer Biomet (ZBH) stock rose 1.8% after Wells Fargo upgraded it to Overweight with a $123 price target, citing the upcoming Monogram robotic system launch. Stifel raised its target to $140, while BMO lowered its target to $101. The stock gained despite broader market declines, reaching an intraday high of $104.28.

$ZBHMed

What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call

Zimmer Biomet (ZBH) reported Q3 sales growth of 13% in technology, bone cement, and surgical sales, but a 2.6% decline in global knee sales. CEO Tornos attributed knee underperformance to commercial execution. The company expects to launch its Monogram robotic system in early 2027. Q3 adjusted earnings were $1.90 per share, with margins declining but cash flow rising. Full-year sales growth guidance was raised to 4.4%-4.9%.